Asthma Management Guidelines

Introduction to Asthma Treatment

The American College of Chest Physicians evidence-based clinical practice guidelines recommend against the use of albuterol (whether oral or inhaled) for patients with acute or chronic cough not due to asthma, with a Grade D recommendation indicating no benefit 1

For asthmatic patients with cough, the American College of Chest Physicians recommends inhaled short-acting beta2-agonists (SABAs) as the treatment of choice for relief of acute symptoms, with albuterol delivered via metered-dose inhaler (MDI) with spacer or nebulizer being the preferred option 3
Inhaled SABAs provide rapid, dose-dependent bronchodilation with minimal side effects, with an onset of action within 5 minutes, peak effect at 30-60 minutes, and duration of 4-6 hours 4
The American College of Allergy, Asthma, and Immunology recommends inhaled corticosteroids (ICS) as first-line treatment for patients with chronic cough due to asthma, with the option to step up the ICS dose and add a leukotriene inhibitor if response is incomplete 5

Proper inhaler technique is essential for effective medication delivery, and patients should be regularly assessed for correct technique, according to the American Academy of Pediatrics 6 and other guideline societies, as reported by the Journal of Allergy and Clinical Immunology 3
However, the fact that proper inhaler technique is essential is also mentioned in 7, but since it is from 'Praxis Medical Insights', we will use 3 and 6 instead

Increasing use of SABA treatment or use more than 2 days per week for symptom relief generally indicates inadequate asthma control and the need for initiating or intensifying anti-inflammatory therapy, as stated by the American College of Allergy, Asthma, and Immunology 3
Using albuterol more than twice weekly for symptom control suggests inadequate control and the need for controller medication, according to the American Thoracic Society, as reported by the Journal of Allergy and Clinical Immunology 3

Oral short-acting beta2-agonists are less potent, take longer to act, and have more side effects compared with inhaled short-acting beta2-agonists, and their use is strongly discouraged by the American Academy of Family Physicians 2

For patients with known pre-existing asthma who experience anaphylaxis, administration of an asthma-reliever medication (such as inhaled albuterol) may provide adjunctive therapy for wheezing, coughing, and shortness of breath, but does not replace epinephrine in anaphylaxis management, as recommended by the American Academy of Pediatrics 6